This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bukowski, R. M. Articles by Finke, J. Search for Related Content PubMed PubMed Citation Articles by Bukowski, R. M. Articles by Finke, J.

Interferon- and CXC Chemokine Induction by Interleukin 12 in Renal Cell Carcinoma¹

Departments of Hematology and Medical Oncology [R. M. B., L. M., T. O., D. P., G. T. B.], Cancer Center Experimental Therapeutics Program [R. M. B., L. M., T. O., D. P., D. M., G. T. B., J. F.], and Departments of Immunology [R. M. B., P. R., L. M., C. S. T., T. A. H., J. F.], Clinical Pathology [R. T.], and Urology [A. N., J. F.], The Cleveland Clinic Foundation, Cleveland, Ohio 44195

Interleukin 12 (IL-12) is known to play an important role in the development of an antitumor response. Its activity has been shown to be dependent upon the intermediate production of IFN- and the influx into the tumor of CD8 lymphocytes. In a murine model, tumor regression induced by IL-12 treatment correlated with IFN-, IP-10, and Mig expression in the tumor bed and was abrogated by antibodies to both chemokines. Here we examined the effects of rHuIL-12 on IFN- and CXC chemokine gene expression in patients with renal cell carcinoma (RCC) in an attempt to determine whether a similar series of molecular events leading to IL-12-mediated tumor regression in mice is also detectable in humans. As in the murine RENCA model, cultured RCC cells themselves could be induced by IFN- to synthesize IP-10 and Mig mRNA. Explanted RCC produced IFN- and IP-10 mRNA in response to IL-12 treatment, which was consistent with the finding that biopsied RCC tumors from IL-12-treated patients also variably expressed augmented levels of those molecules after therapy. Although Mig mRNA was present in the majority of biopsied tumors prior to treatment, both the Mig and IP-10 chemokines as well as IFN- were induced in the peripheral blood mononuclear cells of IL-12-treated patients. Skin biopsies of IL-12-treated patients also all synthesized IP-10 mRNA. This study demonstrates that recombinant human IL-12 therapy of patients with RCC has the potential to induce the expression of gene products within the tumor bed that may contribute to the development of a successful antitumor response.

This article has been cited by other articles:

				T. Ramirez-Montagut, A. Chow, A. A. Kochman, O. M. Smith, D. Suh, H. Sindhi, S. Lu, C. Borsotti, J. Grubin, N. Patel, et al. IFN-{gamma} and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease J. Immunol., August 1, 2007; 179(3): 1669 - 1680. [Abstract] [Full Text] [PDF]

				A. V. Gorbachev, H. Kobayashi, D. Kudo, C. S. Tannenbaum, J. H. Finke, S. Shu, J. M. Farber, and R. L. Fairchild CXC Chemokine Ligand 9/Monokine Induced by IFN-{gamma} Production by Tumor Cells Is Critical for T Cell-Mediated Suppression of Cutaneous Tumors J. Immunol., February 15, 2007; 178(4): 2278 - 2286. [Abstract] [Full Text] [PDF]

				O. Wald, I. D. Weiss, H. Wald, H. Shoham, Y. Bar-Shavit, K. Beider, E. Galun, L. Weiss, L. Flaishon, I. Shachar, et al. IFN-{gamma} Acts on T Cells to Induce NK Cell Mobilization and Accumulation in Target Organs. J. Immunol., April 15, 2006; 176(8): 4716 - 4729. [Abstract] [Full Text] [PDF]

				J. M. Roda, R. Parihar, C. Magro, G. J. Nuovo, S. Tridandapani, and W. E. Carson III Natural Killer Cells Produce T Cell-Recruiting Chemokines in Response to Antibody-Coated Tumor Cells Cancer Res., January 1, 2006; 66(1): 517 - 526. [Abstract] [Full Text] [PDF]

				K. Johrer, C. Zelle-Rieser, A. Perathoner, P. Moser, M. Hager, R. Ramoner, H. Gander, L. Holtl, G. Bartsch, R. Greil, et al. Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma Clin. Cancer Res., April 1, 2005; 11(7): 2459 - 2465. [Abstract] [Full Text] [PDF]

				R. Parihar, P. Nadella, A. Lewis, R. Jensen, C. De Hoff, J. E. Dierksheide, A. M. VanBuskirk, C. M. Magro, D. C. Young, C. L. Shapiro, et al. A Phase I Study of Interleukin 12 with Trastuzumab in Patients with Human Epidermal Growth Factor Receptor-2-Overexpressing Malignancies: Analysis of Sustained Interferon {gamma} Production in a Subset of Patients Clin. Cancer Res., August 1, 2004; 10(15): 5027 - 5037. [Abstract] [Full Text] [PDF]

				G. Alatrash, T. E. Hutson, L. Molto, A. Richmond, C. Nemec, T. Mekhail, P. Elson, C. Tannenbaum, T. Olencki, J. Finke, et al. Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma J. Clin. Oncol., July 15, 2004; 22(14): 2891 - 2900. [Abstract] [Full Text] [PDF]

				S. Mitola, M. Strasly, M. Prato, P. Ghia, and F. Bussolino IL-12 Regulates an Endothelial Cell-Lymphocyte Network: Effect on Metalloproteinase-9 Production J. Immunol., October 1, 2003; 171(7): 3725 - 3733. [Abstract] [Full Text] [PDF]

				E. M. Messing, J. Manola, G. Wilding, K. Propert, J. Fleischmann, E. D. Crawford, J. E. Pontes, R. Hahn, and D. Trump Phase III Study of Interferon Alfa-NL as Adjuvant Treatment for Resectable Renal Cell Carcinoma: An Eastern Cooperative Oncology Group/Intergroup Trial J. Clin. Oncol., April 1, 2003; 21(7): 1214 - 1222. [Abstract] [Full Text] [PDF]

				T. E. Hutson, L. Molto, T. Mekhail, P. Elson, J. Finke, C. Tannenbaum, E. Borden, R. Dreicer, T. Olencki, and R. M. Bukowski Phase I Trial of Consensus Interferon in Patients with Metastatic Renal Cell Carcinoma: Toxicity and Immunological Effects Clin. Cancer Res., April 1, 2003; 9(4): 1354 - 1360. [Abstract] [Full Text] [PDF]

				S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma} J. Immunol., January 1, 2003; 170(1): 400 - 412. [Abstract] [Full Text] [PDF]

				M. Strasly, F. Cavallo, M. Geuna, S. Mitola, M. P. Colombo, G. Forni, and F. Bussolino IL-12 Inhibition of Endothelial Cell Functions and Angiogenesis Depends on Lymphocyte-Endothelial Cell Cross-Talk J. Immunol., March 15, 2001; 166(6): 3890 - 3899. [Abstract] [Full Text] [PDF]